Tourmaline Bio, Inc.
March 22, 2024 - by Joey Ramson
Shares of $TRML have nearly halved over the past two trading sessions after its rival, Tokyo-based Chugai Pharmaceutical unveiled disappointing results in their own study. Both companies are developing drugs centered around blocking an inflammatory cytokine called IL-6.
